The University of Texas at Tyler Libraries

Cover; Drugs During Pregnancy and Lactation; Copyright; Contents; List of Contributors; Preface; Disclaimer; 1 - General commentary on drug therapy and drug risks in ­pregnancy; 1.1 Introduction; 1.2 Development and health; 1.3 Reproductive stages; 1.4 Reproductive and developmental toxicology; 1.5 Basic principles of drug-induced reproductive and developmental toxicology; 1.6 Effects and manifestations; 1.7 Pharmacokinetics of drugs in pregnancy; 1.8 Mechanisms of developmental toxic agents; 1.9 Causes of developmental disorders; 1.10 Embryo/fetotoxic risk assessment and plausibility

1.11 Classification of drugs used in pregnancy1.12 Paternal use of medicinal products; 1.13 Communicating the risk of drug use in pregnancy; 1.14 Risk communication prior to pharmacotherapeutic choice; 1.15 Risk communication regarding the safety of drugs already used in pregnancy; 1.16 Teratology information centers; References; 2 - Specific drug therapiesduring pregnancy; 2.1 - Analgesics, non-steroidal anti-­inflammatory drugs (NSAIDs), muscle relaxants, and antigout medications; 2.1.1 Paracetamol (acetaminophen); 2.1.2 Acetylsalicylic acid; 2.1.3 Pyrazolone compounds and phenylbutazone

2.1.4 Analgesic drug combination products and drugs used for osteoarthritis2.1.5 Opioid agonists and antagonists and other centrally acting analgesics; 2.1.6 Non-steroidal anti-inflammatory and antirheumatic drugs; 2.1.7 Migraine therapy; 2.1.8 Muscle relaxants and other analgesics; 2.1.9 Antigout preparations; References; 2.2 - Allergy and hyposensitization therapy; 2.2.1 Antihistamines (H1-blocker); 2.2.2 Hyposensitization therapy; 2.2.3 C1-Esterase inhibitor deficiency; References; 2.3 - Antiasthmatic and cough ­medication; 2.3.1 Selective β2-adrenergic agonists

2.3.2 Inhaled corticosteroids (ICSs)2.3.3 Theophylline; 2.3.4 Leukotriene antagonists; 2.3.5 Mast cell stabilizers (inhibitors); 2.3.6 Anticholinergics; 2.3.7 Omalizumab and roflumilast; 2.3.8 Expectorants and mucolytic agents; 2.3.9 Antitussives; 2.3.10 Non-selective β-adrenergic agonists; References; 2.4 - Nausea and vomiting in pregnancy; 2.4.1 Treatment options; 2.4.2 Complementary treatment options; 2.4.3 Pharmacological treatment options; 2.4.4 Dopamine antagonists; 2.4.5 Pyridoxine (vitamin B6); 2.4.6 Vitamin B1; 2.4.7 Serotonin antagonists; 2.4.8 Glucocorticoids

2.4.9 Other antiemeticsSummary; References; 2.5 - Gastro-intestinal medications, hypolipidemic agents and ­spasmolytics; 2.5.1 Antacids; 2.5.2 Sucralfate and pirenzepine; 2.5.3 H2 receptor antagonists; 2.5.4 Proton pump inhibitors; 2.5.5 Bismuth salts; 2.5.6 Helicobacter pylori therapy; 2.5.7 Digestives and carminatives; 2.5.8 Atropine and other anticholinergic spasmolytics; 2.5.9 Cholinergics; 2.5.10 Constipation during pregnancy; 2.5.11 Antidiarrheal agents; 2.5.12 Medications for inflammatory bowel disease; 2.5.13 Chenodeoxycholic acid and ursodeoxycholic acid; 2.5.14 Lipid lowering agents

2.5.15 Appetite suppressants, weight loss medications, and obesity

Drugs During Pregnancy and Lactation, 3rd Edition is a quick and reliable reference for all those working in disciplines related to fertility, pregnancy, lactation, child health and human genetics who prescribe or deliver medicinal products, and to those who evaluate health and safety risks. Each chapter contains twofold information regarding drugs that are appropriate for prescription during pregnancy and an assessment of the risk of a drug when exposure during pregnancy has already occurred. Thoroughly updated with current regulations, references to the latest pharmacological data, and new

Description based upon print version of record.